Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the third quarter, fueled by continued gains in technology and falling bond yields. Easing tariff rhetoric and renewed AI infrastructure investments boosted large tech stocks. […]
WHO recommends GLP-1 drugs for obesity
The World Health Organization on Monday recommended GLP-1 drugs as a tool to manage obesity in adults, marking a shift in the way the U.N. agency has historically framed obesity treatment.
It’s official: Global health body makes historic call on weight-loss drugs
The World Health Organization (WHO) has finally made its recommendations on using glucagon-like peptide-1 (GLP-1) therapeutics for weight loss, though it remains to be seen whether it changes their status for prescribing or their price. Continue Reading Category: Obesity, Illnesses and conditions, Body and Mind Tags: World Health Organization, Obesity, GLP-1 receptor agonists, Semaglutide, Weight […]
WHO says weight loss drugs are ‘new chapter’ in fight against obesity – The Guardian
WHO says weight loss drugs are ‘new chapter’ in fight against obesity The Guardian WHO recommends GLP-1 drugs for obesity NBC News WHO Sets GLP-1 Weight-Loss Drug Guidelines Scientific American From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults World Health Organization (WHO) Ozempic-style drugs should be […]
WHO Unveils GLP-1 Guidelines
New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly
Stopping GLP-1 drugs before pregnancy leads to more weight gain
Researchers determine the risk of pregnancy weight gain in patients who were prescribed GLP-1 RAs prior to conception.
WHO endorses weight-loss drugs to tackle obesity epidemic
The WHO has endorsed GLP-1 agonists like Ozempic as a key tool to treat the global obesity epidemic, providing new guidelines for this chronic disease. Read More: https://punchng.com/who-endorses-weight-loss-drugs-to-tackle-obesity-epidemic/
WHO recommends GLP-1 drugs for obesity – NBC News
WHO recommends GLP-1 drugs for obesity NBC News WHO says weight loss drugs are ‘new chapter’ in fight against obesity The Guardian World Health Organization issues first-ever guidelines for use of GLP-1 weight loss medications ABC News WHO warning over shortage of obesity jabs BBC Ozempic-style drugs should be available to all, not just the rich, says WHO politico.eu
Home hospital care demonstrates success in rural communities
One in five people in the United States live in a rural area. Patients in rural communities often struggle to access care because of travel difficulties, high costs and limited resources, leading to worse medical outcomes. With over 150 rural hospital closures since 2010, innovative approaches to care delivery in rural areas are needed.
Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program
Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug purchased through LillyDirect. Both pharmas recently struck a deal with the White House for cheaper prices via the yet-to-be-launched TrumpRx.